Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

939
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
939
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

811
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

3.1K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
3.1K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.6K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of SGLT2 inhibitors in patients with Fabry disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease.

Molecular genetics and metabolism·2026
Same author

A Novel N-Terminal Pro-B-Type Natriuretic Peptide Assay in the Early Diagnosis of Acute Heart Failure.

JACC. Advances·2025
Same author

Identification of genetic variants associated with Fabry nephropathy progression using whole-exome sequencing.

Molecular genetics and metabolism·2025
Same author

Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides.

European journal of heart failure·2025
Same author

Prognostic value of health-related quality of life in patients with acute dyspnoea: a cohort study.

Swiss medical weekly·2025
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.5K

The cardiorenal problem.

Emiliy Pollock1, Albina Nowak1

  • 1Division of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.

Swiss Medical Weekly
|December 5, 2014
PubMed
Summary
This summary is machine-generated.

Cardiorenal syndrome (CRS) involves harmful interactions between heart and kidney dysfunction, affecting many patients. New serum markers may improve CRS diagnosis, with diuretics and ACE inhibitors as primary treatments.

More Related Videos

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

18.9K
How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

13.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.5K
Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

18.9K
How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

13.0K

Area of Science:

  • Cardiology
  • Nephrology
  • Internal Medicine

Background:

  • Cardiorenal syndrome (CRS) is a prevalent condition characterized by the detrimental interplay between cardiac and renal dysfunction.
  • CRS has a high mortality rate and encompasses five clinical subtypes.
  • Common pathogenetic mechanisms include neurohumoral and hemodynamic derangements.

Purpose of the Study:

  • To discuss the complex interactions in cardiorenal syndrome.
  • To introduce novel serum markers for improved diagnosis of CRS.
  • To review current therapeutic strategies for CRS.

Main Methods:

  • Literature review of cardiorenal syndrome pathophysiology and treatment.
  • Discussion of emerging diagnostic serum markers.
  • Analysis of established therapeutic interventions.

Main Results:

  • Novel serum markers show promise for enhancing CRS diagnosis compared to traditional creatinine measurements.
  • Loop diuretics are the mainstay for acute CRS management.
  • ACE-inhibition is crucial for chronic CRS, often continued despite creatinine increases.

Conclusions:

  • CRS is a significant clinical challenge requiring improved diagnostic tools.
  • Current therapies focus on diuretics and ACE inhibitors.
  • Further research into diagnostic markers and treatment optimization is warranted.